RAPID-I is a double blind, placebo controlled, multi-centre trial investigating the use of infliximab in the treatment of pancreatitis. The RAPID-I team aim to recruit 290 patients from hospitals across the UK with a new diagnosis of acute pancreatitis. Acute pancreatitis is a common and serious condition that is lacking a specific treatment. The disease causes severe pain and gastrointestinal problems, leading to patients having to remain in hospital for a long time. Many treatments have been tested to treat acute pancreatitis, but none cure the illness or accelerate recovery.